In the present study we investigated in vivo therapeutic potential of DCs vaccines in B-cell chronic lymphocytic leukemia (B-CLL). On the day 0 the SCID mice were intraperitoneally inoculated with peripheral blood mononuclear cells (PBMC) of B-CLL patients at a dose of 10-30 × 10 6 and left untreated (controls) or i.p. injected on the day 7 with 0.2 -14.0 × 10 6 dendritic cells. DCs were generated in vitro from peripheral blood monocytes of B-CLL donors (autologous DCs) or healthy donors (allogeneic cells) and pulsed with B-CLL antigens. On the day 14, the effect of implanted cells interactions was evaluated by a counting of CD19+CD5+ human leukemic cells and human T cells in the peritoneal fluid of mice. We found, that mean numbers of CD19+CD5+ leukemic cells as well as human T cells were lowered in peritoneal fluid of mice treated with allogeneic APCs.. However, we did not observe similar effects with autologous DCs.
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is a most frequent type of leukemia of adults in Western world [1] . Since it is a slow growing malignancy, the time allows for an immunotherapy attempts against the tumor cells to be generated by vaccination [2, 3] . It is easy to obtain tumor cells for vaccine production, as the leukemia cells circulate in large amounts in peripheral blood. The positive clinical observations in patients vaccinated with the irradiated autologous leukemia cells could be explained by hypothesis of dendritic cells (DC) activity [4, 5] . DCs are the most potent cancer antigen's presenting cells that initiate effective T-cell response [6, 7] observed as the result of these vaccinations. The active DCs have been shown in clinical observations of melanoma and prostate carcinoma [8, 9, 10] . They have also been used with some success to generate an immune response against idiotype peptides in patients with follicular B-cell lymphoma [11] . It has been shown that functional DCs can be generated from peripheral blood monocytes of B-CLL patients in early stages of the disease [12, 13] . The DCs stimulated with tumor antigens from leukemic cell lysates or apoptotic bodies induced in vitro strong response of specific cytotoxic T lymphocytes (CTLs) [14, 15] .
Several problems of DCs activity are unknown, and may be asked in model experiments. SCID (severe combined immunodeficiency) mice have been proved a useful model for studies of autoimmune diseases as well as cancer diseases, including B-CLL [16, 17] . We established a SCID mouse xenotransplant model to study the effect of DCs on human BCLL cells counts [18] . In the present study, we implanted leukemic cells into peritoneal cavity of SCID mice, then the animals received human autologous or allogeneic monocytederived DCs pulsed with tumor cell lysates or irradiat-ed leukemia cells in order to compare in vivo therapeutic potential of both DCs vaccines in B-CLL.
Materials and methods
Mice. The pathogen-free, 10-12 weeks-old severe combined immunodeficient (SCID) mice (BALB/c C.B-17/IcrHanHsd-scid [19] were our own breeding; first families were from Harlan Shaw's Farm, UK. The animals were housed in sterilized microisolator cages and received vitamins, autoclaved food and drinking water. The mice were systematically controlled for the absence of peripheral blood B and T lymphocytes with antimouse CD19 PE (clone ID3) and anti-mouse CD3 FITC (clone 17A2), (Pharmingen).
Before the implantation of human cells the animals were immunosupressed by s.c. injection of cyclofosfamide, 3mg/animal on the day 3 and the day 2 before inoculation of the human cells [20, 21] . Then the animals were treated every 2-3 days s.c. with hybridoma PK136 cells culture supernatant containing the anti-NK1.1 monoclonal antibodies (4 μg IgG) to suppress mice NK cells activity [22] . The experiment protocol was accepted by Local Ethic Commision for Animal Experiments (Nr KE 271/2003).
Cell donors: leukemic patients and healthy donors. B-cells for implantation were obtained from untreated patients in 0-2 stage according to Rai [23] (Table 1 ). The peripheral blood samples (20 ml) were collected on heparin after informed consent obtained from the patient in accordance with the Declaration of Helsinki and with the approval by the Local Ethics Committee of the Medical University at Lublin (KE-0254/239/2002). The peripheral blood samples (40ml) from patients and healthy donors for preparation of dendritic cells were collected similarly. Generation of autologous and allogeneic DCs. Dendritic cells were generated from peripheral blood monocytes according to previously described procedures [13] . Briefly, mononuclear cells isolated from 40 mL of peripheral blood taken from patients with BCLL and healthy donors were used. Cells were allowed to adhere to plastic dishes for 90 min. at 37°C. Thereafter the adherent fraction of PBMC was cultured in a medium containing RPMI-1640 supplemented with 2% human albumin (ZLB Bioplasma AG, Bern, Switzerland), penicillin 100 IU /ml, streptomycin 50mg/ml, neomycin 100mg/ml). On day 1, 3 and 5 of the culture, 1.000 IU/ml rhGM-CSF (Leucomax, Novartis, Basel, Switzerland) and 500 ng/ml rhIL-4 (Strathmann, Hannover, Germany) were added to the culture medium. On day 6, the lysates of 7x107 autologous leukemic B-cells were used for the pulsing of the DCs. On day seven, 50 ng/ml rhTNF-α was added to the culture and the cells were stimulated for 2 h. Thereafter cells were collected, washed twice in 0.9% NaCl and resuspended in 0.5-1.0 mL of 0.9% NaCl. Before implantation, the suspension of DCs cell populations were analyzed as described for PBMC, and finaly DCs at a dose: DCauto 0.5 to 14 × 10 6 , while DCallo 0.2 to 2 × 10 6 cells per mouse were injected intraperitoneally. Characterization of the dendritic cells suspensions are in Table 2 (see results) . Table 1 . Clinical and laboratory characteristics of B-CLL patients, whose cells were implanted into SCID mice. Normal range of WBC/lymphocytes: 4-10/0.8-4.3(G/l). 2-M 0.8-2.2mg/L; abnormal values are marked with asterisk for ZAP-70, CD38, 2-M; stages according to Rai [23] ; clinical response for autoDC vaccines (see results): RS -response, SD -stable disease, NR -no response; Abbreviations: N -normal; ND -not done, NT -not treated.
Analysis of B-CLL counts after autologous and allogeneic
ity of the animal was analyzed. First the animal was sacrified, then the peritoneal cavity was washed out with 2 ml of the sterile physiological salt solution and cells were analyzed in that suspension.
Flow cytometry and statistics. The number of peritoneal cavity cells was counted and the number of human populations CD45+, CD5+/CD19+, and CD3+ per animal were analyzed as described above for cells before implantation. Cross-reaction of the antihuman leukocyte antibodies with mice leukocytes was not observed. The cells were analyzed by flow cytometry (Becton Dickinson FACSCalibur) in CellQuest application (3.2.1f1). Nonparametric statistics was used. The median value and percentile values (P25 and P75) were calculated for results of experiments and the statistically significant difference of results was assumed for p<0.05 in Mann-Whitney U-test.
Results
The characteristics of chronic B-lymphocytic leukemia patients participating in experiments with DC are summarized in Table 1 . All patients, 47-69 years old, were diagnosed with B-CLL in early stages (Rai 0-2), according to NCI (National Cancer Institute) criteria, and were previously untreated. The results of peripheral blood leukocytes and laboratory tests of patients including analyzes of leukemia cells ZAP-70 and CD38 were assayed.
The patients were treated later clinically with autological DCs vaccines and the clinical result of treatment is included in the Table 1 . The patients who showed a 25% or higher reduction in their WBC count after vaccination were considered responders (RS), patients with less than 25% reduction -stable disease (SD), and patients with an increase of their WBC -non responders (NR). Most patients responded for the DCs vaccines with stable disease (SD).
Evaluation of conditions for the experiment
In the initial part of the study [18] , mouse xenotransplant model was established. For this, SCID mice were inoculated with B-CLL patients' PBMC at different doses ranging from 10.0 to 150.0 × 10 6 cells per mouse. The optimal range of implanted PBMC was established for 10-30 × 10 6 /animal, as used in the present experiments. It was observed, that ip implanted hemopoietic cells remain locally and are not distributed significantly to the spleen, bone marrow or peripheral blood of the mouse [18] (Fig.1D) Characterization of the lymphocytes implanted with the suspension of dendritic cells is presented in Table 2 . With allogeneic DCs the allogeneic T lymphocytes were applied.
The animals with implanted B-CLL cells appeared healthy within the period of experiment. The number of B-CLL cells and T lymphocytes implanted was a sum of the cells given at day zero and the cells added at day 7 with suspension of DC. The final analysis was at day 14 from implantation of human leukemia cells and it appeared, that from implanted cells, only 0.23 × 10 6 were recoverd (1.7%) at analysis (Table 3) . In two experiments, the immunosupression with monoclonal anti-NK1.1 only was attempted, but the suppression was uncomplete and these results were not included in the final analysis.
Cell populations in control animals
The number of human cell populations from different patients in control animals is presented in Table 4 . The recovered number of human subpopulations of hemopoietic CD45+ cells is the sum of leukemia B cells CD19+/CD5+ (333 × 10 3 ), normal T CD3+ cells (17 × 10 3 ), and probably normal B cells (Fig.1A,B,  C) . The presence of T cells subpopulation is important for possible interaction with DCs in process of crosspresentation and stimulation of T cells response. In some experiments human HLAABC positive cells were tested and were observed (not presented in details). 
Autologous or allogeneic DCs interaction with lymphocytes
Results in control animals with implanted patient's leukemia B-CLL cells without DC were compared with that from animals with B-CLL cells from the same patient that additionally have implanted auto-DC or allo-DC activated with the same patient's leukemia cells lysate and TNF. At the day 7 from implantation of allogeneic DC to animals, the CD45+ hemopoietic cells and leukemia B cells CD5+/CD19+ populations were significantly lower as compared with the control animals ( Table 5 ). The number of cells in the populations CD19+ B cells and CD3+ T cells had a tendency to decrease. The result may be interpreted as in vivo *mean from 2-6 animals from the same patient; patient #6 was the donor for two experiments; patient #2 was excluded from calculations as the result was analyzed at day 9th MLC (mixed lymphocyte culture) interaction between patient's lymphocytes and T cells of donor DCs, something like acute graft versus host (GVH) response. It is not the result of activating interaction between allogeneic DCs and patients T lymphocytes, because the number of T cells is decreasing similarly as the number of leukemia cells.
There were no significant differences in the counts of cell populations CD45+, CD19+, CD5+/CD19+ in animals treated with autologous DC cells as compared to the control animals. However, there is a tendency of CD3+ T cells number to increase, nearly three times, from 17×10 3 /animal in controls to 48×10 3 /animal in DCs implanted, a possible result of DC autologous and T cells activating interaction, and proliferation of T cells. Results are presented in Table 5 .
Discussion
Despite the results of in vitro studies showing that functional DCs can be generated from peripheral blood monocytes of patients with B-CLL [14] , and the specific CTL against B-CLL cells could be achieved using DCs pulsed with leukemic antigens [25] , so far, there was only one reported clinical trial on DCs immunotherapy in B-CLL [13] . Therefore, we have established a SCID mouse model to study in vivo, the effect of DCs vaccinations on the number of B-CLL Table 4 . The analysis of human cells populations in peritoneal cavity of particular 27 SCID mice at day 14 after ip inoculation with peripheral blood mononuclear cells of B-CLL patients without (control) or with post-injection (on day 7) with human allogeneic or autologous dendritic cells (DCallo, DCauto, respectively). M = median value, (P25-P75) = 25 and 75 percentile values.
cells. In the initial part of experiment [18] we transplanted different doses of PBMC isolated from patients with B-CLL with an intend to evaluate the distribution as well as the count of leukemic cells in different tissues, such as peripheral blood, bone marrow, peritoneal cavity, spleen and liver. We found, that high number of inoculated cells (150.0 × 10 6 ) induced death of animals [18] , and if the number of implanted PBMC did not exceed 50.0-90.0 × 10 6 /per mouse, leukemic cells were eliminated within 60 days. Similar observations, concerning correlations between survival time and a number of implanted B-CLL cell line were reported by Kawata et al. [26] . We have also found individual differences in the survival time between animals transplanted with similar dose of cells from different patients, resulting probably from different activity and proliferative potential of leukemic cells in individual patients, as well as from heterogeneic clinical course of B-CLL. In the other study survival time of SCID mice inoculated with T-CLL cells at a dose 40.0 × 10 6 ranged from 43 to 69 days [27] . In our study, even higher dose was eliminated from mice that may result from more aggressive character of T-CLL comparing to B-CLL.
After intraperitoneal implantation of PBMC isolated from patients with B-CLL, CD19+CD5+ cells were found at 14 days in small number in peripheral blood, bone marrow, and spleen of mice as compared to peritoneal cavity [18] . In the study of Hummel et al. [17] , after intravenous injection of PBMC obtained from B-CLL patients, leukemic cells were found the most often in the spleen, lungs, bone marrow and kidneys.
Thus, distribution of leukemic cells in mice may depend on the route of injection, and the different chemokines secreted by spleen and bone marrow stromal cells [28] . The stromal cells of mice peritoneum are known from secretion of SDF-1 chemokine [29, 30] , and leukemia B-CLL cells express the CXCR4 receptor. That may, at least partly, explain homing of leukemia cells at peritoneal site of implantation.
Gradual elimination of leukemic cells from SCID mice organisms observed in our study was probably the effect of residual activity of immune system. Even so, there are no active B or T cells in SCID mice [19] , increased activity of NK cells as well as normal function of granulocytes and macrophages was reported. That is why, before implantation of human peripheral blood cells, mice were treated with cyclophosphamide in order to suppress residual activity of their own immune system. Immunosuppressive effect of cyclophosphamide lasts for about 2 weeks and this restricted time of our observations to 14 days.
The main problem with B-CLL studies on SCID mouse model is, that high dose of implanted human leukemia cells instead of long lasting chronic stage of B-CLL form, induce rapid death of animals due to secondary tumours. It was found, that the reason was the latent form of Epstein-Barr virus (EBV) present in mice organisms, that activated under immunosuppressive conditions transformation of B-CLL lymphocytes in aggressive lymphoma cells causing the death of mice within 8-16 weeks [31] . According Kobayashi et al. [32] aggressive B-cell lymphomas, causing the death of animals in short time after B-CLL cells transplantation, origin not from leukemic cells, but from bystander B cells infected with EBV. In our study, the evaluation of human DCs effect was studied within two weeks after B-CLL cells implantation, so previous to both elimination of inoculated cells, as well as prospective development of aggressive B-cell lymphomas connected with EBV infection.
We observed, that the number of B-CLL cells in peritoneal fluid was lower in mice treated with allogeneic DCs, comparing to the mice that received only leukemic cells. In this system we observed acute graft versus host (GVH) response between human allogeneic implanted cells within the mouse peritoneal cavity. This is suggested by the parallel decrease of human B-CLL and T cells, as allogeneic DCs presentation of leukemia antigens would activate T cells for proliferation rather, and not the observed T cells killing.
The observed unresponsiveness of patients own T lymphocytes to autologous dendritic cells may be partly explained by B-CLL patient's DCs defective phagocytosis recently recorded [3] . We observed, that the vaccination of patients with the irradiated leukemia cells improve of DCs phagocytotic activity. The autologous DCs applied in the present SCID mouse experiment were from patients before vaccination. However, the observed number of T cells at time of analysis was already nearly 3-times higher in animals treated with autologous DCs as compared to control animals. The result suggests crosspresentation of leukemia antigens by DCs to autologous T cells inducing proliferation of these cells.
In conclusion, in the present study we established a model of B-CLL cells implantation into SCID mice, than on this model the in vivo effects of DCs immunotherapy were evaluated. In experimental model, we found tendency to rise of human T cells in animals treated with autologous DCs that were from unvaccinated B-CLL patients. These observation confirm deficiency of DCs in the unvaccinated patients recently recorded.
The result of experiment with allogeneic DCs resemble acute GVH response. However, the correlation between clinical response and experimental data from mice model remains equivocal and requires further studies. It seems worth to continue the presented studies on SCID mouse model in order to improve the efficacy of DCs immunotherapy in B-CLL patients.
